Hepatic Arterial Phase Images Research Articles

Enhancement patterns of malignant gallbladder masses at multiphasic contrast-enhanced CT: Associations with clinicoradiopathological features

PurposeTo assess the enhancement patterns of malignant gallbladder masses at multiphasic contrast enhanced computed tomography (CECT) and their association with the clinicoradiopathological features. Material and methodsIn this retrospective study, consecutive patients with mass-forming gallbladder cancer (GBC) who underwent biphasic [hepatic arterial phase (HAP) and portal venous phase (PVP)] CECT between January 2019 and January 2023 were included. The enhancement patterns at CT scans were assessed independently by two radiologists blinded to the clinicopathological data. The masses were categorized into the typical group (hypoattenuation relative to normal liver in HAP) and the atypical group (isoenhancement or hyperenhancement in HAP). Enhancement patterns in PVP were also evaluated. The association between enhancement characteristics and the pathological grade and type, radiological aggressiveness (biliary/ vascular involvement, lymph node, liver, and omental metastases), resectability, and overall survival was assessed. ResultsSixty-five patients (41 females, mean age was 52.5 ± 17.6 years) were included in the study. On HAP images, eight lesions (12.3%) were hyperattenuating, nine (13.8%) were isoattenuating, and 48 (73.8%) were hypoattenuating. Of the 17 masses in the atypical group, 8 (47.1%) lesions showed washout, and 9 showed persistent enhancement (52.9%) in the PVP. Heterogeneous peripheral and central enhancement in HAP was significantly associated with lymph node metastases (p=0.019). Enhancement pattern was not significantly associated with pathological grade/type, other radiological features, resectability, and overall survival. ConclusionMass-forming GBC has variable enhancement. Heterogeneous HAP enhancement is associated with lymph node metastases.

Optimal Parameters for Virtual Mono-Energetic Imaging of Liver Solid Lesions

Objective To explore the optimal parameters for virtual mono-energetic imaging of liver solid lesions. Methods A retrospective analysis was performed on 60 patients undergoing contrast-enhanced spectral CT of the abdomen.The iodine concentration values of hepatic arterial phase images and the CT values of different mono-energetic images were measured.The correlation coefficient and coefficient of variation were calculated. Results The average correlation coefficients between iodine concentrations and CT values of hepatic solid lesion images at 40,45,50,55,60,65,and 70 keV were 0.996,0.995,0.993,0.989,0.978,0.970,and 0.961,respectively.The correlation coefficients at 40(P=0.007),45(P=0.022),50 keV (P=0.035)were higher than that at 55 keV,and the correlation coefficients at 40 keV(P=0.134) and 45 keV(P=0.368) had no significant differences from that at 50 keV.The coefficients of variation of the CT values at 40,45,and 50 keV were 0.146,0.154,and 0.163,respectively. Conclusion The energy of 40 keV is optimal for virtual mono-energetic imaging of liver solid lesions in the late arterial phase,which is helpful for the diagnosis of liver diseases.

Effect of Patient Factors on Portal Vein and Hepatic Contrast Enhancement at Computed Tomography Scan With Protocol Combining Fixed Injection Duration and Patients' Body Weight Tailored Dose of Contrast Material.

IntroductionFixed injection duration with patients’ body weight tailored dose of contrast material was recommended as the practical scan protocol in multiphasic contrast-enhanced abdominal computed tomography (CT). This study evaluated the effect of the demographic variables on portal vein and hepatic contrast enhancement in hepatic arterial phase (HAP), aiming to reduce the patient-to-patient variability and optimize the HAP images.MethodsThis retrospective analysis included 87 patients who underwent abdominal enhancement multiphase CT from April to June 2022. All the patients were examined using protocol combining fixed injection duration and patients’ body weight tailored dose of contrast material. Univariate and multivariate linear regression analyses were performed between all patient characteristics and the contrast-enhanced CT number of portal vein and hepatic parenchyma during HAP.ResultsUnivariate linear regression analysis demonstrated statistically significant correlations between the CT number of hepatic parenchyma, and the body mass index (BMI), body surface area (BSA), and total body weight (TBW) (all P < 0.001) during HAP. However, multivariate linear regression analysis showed that the BMI or BMI and age were of independent predictive values (P < 0.001). Also, only the age was independently and negatively related to the CT number of portal vein enhancement during HAP (r = 0.240, P < 0.05) according to univariate linear regression analysis.ConclusionsUnivariate linear regression analysis revealed a significant inverse correlation between portal vein CT value and age. By multivariate linear regression analysis, only the BMI and age were significantly correlated with liver parenchymal enhancement, while gender, TBW, BSA, and HT were not.

The Evaluation of Hepatocellular Carcinoma with Biphasic Contrast Enhanced Spiral CT Scan

Background: Hepatocellular Carcinoma (HCC) is the most common malignant neoplasm of the liver worldwide. Liver cancer ranks third among all cancer deaths in Bangladesh as the clinical presentation is non-specific, the modern imaging modalities can play an important role in the diagnosis of HCC and the radiologist is often the first to suggest the correct diagnosis. With the advent of multi-detector spiral CT, detection and characterization of HCC has markedly improved. Multi-detector spiral CT with its increased spatial and temporal resolution allows multiple perfusion phases of liver to be acquired.Multi-detector biphasic spiral CT techniques have been increasingly promising with respect to accurate preoperative diagnosis and assessment of the extent of HCC. This study was carried out to evaluate the role of biphasic contrast-enhanced spiral CT including Hepatic Arterial Phase (HAP) imaging with Portal Venous Phase (PVP) imaging, in the detection and characterization of HCC.&#x0D; Methods: The study included 35 patients (M=31, F=4) with histopathologically proven HCC. Age range was between 21-75 years (mean=51) by following consecutive patients in whom HCC was diagnosed or suspected either by raised serum a (alpha)-fetoprotein level or byultrasound imaging.&#x0D; Results: Biphasic contrast-enhanced examination in these 35 patients could reveal a total of 65 lesions, out of which 48% were unifocal and 46% were multifocal HCCs. On HAP imaging 92% lesions were detected. (hyper attenuating = 56, hypo attenuating = 4) while on PVP imaging delectability was only 51% (hyper attenuating=2, hypo attenuating=30). Hence delectability was significantly superior in HAP as compared to PVP imaging (p &lt;0.0001, 95% CI 25.2-54.7). In 49% tumor was visible only on HAP images. Venous invasion was present in 11 patients (31%).&#x0D; Conclusion: Biphasic contrast enhanced spiral CT is a useful method in detection and characterization of HCC.&#x0D; Sir Salimullah Med Coll J 2022; 30: 61-66

Optimized scan delay for late hepatic arterial or pancreatic parenchymal phase in dynamic contrast-enhanced computed tomography with bolus-tracking method.

To determine the optimal scan delay corresponding to individual hemodynamic status for pancreatic parenchymal phase in dynamic contrast-enhanced CT of the abdomen. One hundred and fourteen patients were included in this retrospective study (69 males and 45 females; mean age, 67.9 ± 12.1 years; range, 39-87 years). These patients underwent abdominal dynamic contrast-enhanced CT between November 2019 and May 2020. We calculated and recorded the time from contrast material injection to the bolus-tracking trigger of 100 Hounsfield unit (HU) at the abdominal aorta (s) (TimeTRIG) and scan delay from the bolus-tracking trigger to the initiation of pancreatic parenchymal phase scanning (s) (TimeSD). The scan delay ratio (SDR) was defined by dividing the TimeSD by TimeTRIG. Non-linear regression analysis was conducted to assess the association between CT number of the pancreas and SDR and to reveal the optimal SDR, which was ≥120 HU in pancreatic parenchyma. The non-linear regression analysis showed a significant association between CT number of the pancreas and the SDR (p < 0.001). The mean TimeTRIG and TimeSD were 16.1 s and 16.8 s, respectively. The SDR to peak enhancement of the pancreas (123.5 HU) was 1.00. An SDR between 0.89 and 1.18 shows an appropriate enhancement of the pancreas (≥120 HU). The CT number of the pancreas peaked at an SDR of 1.00, which means TimeSD should be approximately the same as TimeTRIG to obtain appropriate pancreatic parenchymal phase images in dynamic contrast-enhanced CT with bolus-tracking method. The hemodynamic state is different in each patient; therefore, scan delay from the bolus-tracking trigger should also vary based on the time from contrast material injection to the bolus-tracking trigger. This is necessary to obtain appropriate late hepatic arterial or pancreatic parenchymal phase images in dynamic contrast-enhanced CT of the abdomen.

Diagnostic value of deep learning reconstruction for radiation dose reduction at abdominal ultra-high-resolution CT.

We evaluated lower dose (LD) hepatic dynamic ultra-high-resolution computed tomography (U-HRCT) images reconstructed with deep learning reconstruction (DLR), hybrid iterative reconstruction (hybrid-IR), or model-based IR (MBIR) in comparison with standard-dose (SD) U-HRCT images reconstructed with hybrid-IR as the reference standard to identify the method that allowed for the greatest radiation dose reduction while preserving the diagnostic value. Evaluated were 72 patients who had undergone hepatic dynamic U-HRCT; 36 were scanned with the standard radiation dose (SD group) and 36 with 70% of the SD (lower dose [LD] group). Hepatic arterial and equilibrium phase (HAP, EP) images were reconstructed with hybrid-IR in the SD group, and with hybrid-IR, MBIR, and DLR in the LD group. One radiologist recorded the standard deviation of attenuation in the paraspinal muscle as the image noise. The overall image quality was assessed by 3 other radiologists; they used a 5-point confidence scale ranging from 1 (unacceptable) to 5 (excellent). Superiority and equivalence with prespecified margins were assessed. With respect to the image noise, in the HAP and EP, LD DLR and LD MBIR images were superior to SD hybrid-IR images; LD hybrid-IR images were neither superior nor equivalent to SD hybrid-IR images. With respect to the quality scores, only LD DLR images were superior to SD hybrid-IR images. DLR preserved the quality of abdominal U-HRCT images even when scanned with a reduced radiation dose. • Lower dose DLR images were superior to the standard-dose hybrid-IR images quantitatively and qualitatively at abdominal U-HRCT. • Neither hybrid-IR nor MBIR may allow for a radiation dose reduction at abdominal U-HRCT without compromising the image quality. • Because DLR allows for a reduction in the radiation dose and maintains the image quality even at the thinnest slice section, DLR should be applied to abdominal U-HRCT scans.

Texture analysis on preoperative contrast-enhanced magnetic resonance imaging identifies microvascular invasion in hepatocellular carcinoma

BackgroundRadiomic texture analysis quantifies tumor heterogeneity. The aim of this study is to determine if radiomics can predict biologic aggressiveness in HCC and identify tumors with MVI. MethodsSingle-center, retrospective review of HCC patients undergoing resection/ablation with curative intent from 2009 to 2017. DICOM images from preoperative MRIs were analyzed with texture analysis software. Texture analysis parameters extracted on T1, T2, hepatic arterial phase (HAP) and portal venous phase (PVP) images. Multivariate logistic regression analysis evaluated factors associated with MVI. ResultsMVI was present in 52.2% (n = 133) of HCCs. On multivariate analysis only T1 mean (OR = 0.97, 95%CI 0.95–0.99, p = 0.043) and PVP entropy (OR = 4.7, 95%CI 1.37–16.3, p = 0.014) were associated with tumor MVI. Area under ROC curve was 0.83 for this final model. Empirical optimal cutpoint for PVP tumor entropy and T1 tumor mean were 5.73 and 23.41, respectively. At these cutpoint values, sensitivity was 0.68 and 0.5, respectively and specificity was 0.64 and 0.86. When both criteria were met, the probability of MVI in the tumor was 87%. ConclusionTumor entropy and mean are both associated with MVI. Texture analysis on preoperative imaging correlates with microscopic features of HCC and can be used to predict patients with high-risk tumors.

Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.

The objective of our study was to assess the diagnostic performance of texture analysis (TA) on gadoxetic acid-enhanced MR images for differentiation of hepatocellular adenoma (HCA) from focal nodular hyperplasia (FNH). This study included 40 patients (39 women and one man) with 51 HCAs and 28 patients (27 women and one man) with 32 FNH lesions. All lesions were histologically proven with preoperative MRI performed with gadoxetic acid. Two readers reviewed all the imaging sequences to assess the qualitative MRI characteristics. The T2-weighted fast spin-echo, hepatic arterial phase (HAP), and hepatobiliary phase (HBP) sequences were used for TA. Textural features were extracted using commercially available software (TexRAD). The differences in distributions of TA parameters of FNHs and HCAs were assessed using the Mann-Whitney U test. Area under the ROC curve (AUROC) values were calculated for statistically significant features. A logistic regression analysis was conducted to explore the added value of TA. A p value < 0.002 was considered statistically significant after Bonferroni correction for multiple comparisons. Multiple TA parameters showed a statistically different distribution in HCA and FNH including skewness on T2-weighted imaging, skewness on HAP imaging, skewness on HBP imaging, and entropy on HBP imaging (p < 0.001). Skewness on HBP imaging showed the largest AUROC (0.869; 95% CI, 0.777-0.933). A skewness value on HBP imaging of greater than -0.06 had a sensitivity of 72.5% and a specificity of 90.6% for the diagnosis of HCA. Six of 51 (11.8%) HCAs lacked hypointensity on HBP imaging. A binary logistic regression analysis including hypointensity on HBP imaging and the statistically significant TA parameters yielded an AUROC of 0.979 for the diagnosis of HCA and correctly predicted 96.4% of the lesions. TA may be of added value for the diagnosis of atypical HCA presenting without hypointensity on HBP imaging.

Evaluation of texture analysis for the differential diagnosis of focal nodular hyperplasia from hepatocellular adenoma on contrast-enhanced CT images.

To explore the value of CT texture analysis (CTTA) for differentiation of focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA) on contrast-enhanced CT (CECT). This is a retrospective, IRB-approved study conducted in a single institution. A search of the medical records between 2008 and 2017 revealed 48 patients with 70 HCA and 50 patients with 62 FNH. All lesions were histologically proven and with available pre-operative CECT imaging. Hepatic arterial phase (HAP) and portal venous phase (PVP) were used for CTTA. Textural features were extracted using a commercially available research software (TexRAD). The differences between textural parameters of FNH and HCA were assessed using the Mann-Whitney U test and the AUROC were calculated. CTTA parameters showing significant difference in rank sum test were used for binary logistic regression analysis. A p value < 0.05 was considered statistically significant. On HAP images, mean, mpp, and skewness were significantly higher in FNH than in HCA on unfiltered images (p ≤ 0.007); SD, entropy, and mpp on filtered analysis (p ≤ 0.006). On PVP, mean, mpp, and skewness in FNH were significantly different from HCA (p ≤ 0.001) on unfiltered images, while entropy and kurtosis were significantly higher in FNH on filtered images (p ≤ 0.018). The multivariate logistic regression analysis indicated that the mean, mpp, and entropy of medium-level and coarse-level filtered images on HAP were independent predictors for the diagnosis of HCA and a model based on all these parameters showed the largest AUROC (0.824). Multiple explored CTTA parameters are significantly different between FNH and HCA on CECT.

Ring-Like Enhancement of Hepatocellular Carcinoma in Gadoxetic Acid–Enhanced Multiphasic Hepatic Arterial Phase Imaging With Differential Subsampling With Cartesian Ordering

The aim of this study was to evaluate the efficacy of multiphasic hepatic arterial phase (HAP) imaging using DISCO (differential subsampling with Cartesian ordering) in increasing the confidence of diagnosis of hepatocellular carcinoma (HCC). This retrospective study was approved by the institutional review board, and the requirement for informed patient consent was waived. Consecutive patients (from 2 study periods) with malignant liver nodules were examined by gadoxetic acid-enhanced magnetic resonance imaging using either multiphasic (6 phases; n = 135) or single (n = 230) HAP imaging, which revealed 519 liver nodules other than benign ones (HCC, 497; cholangiocarcinoma, 11; metastases, 10; and malignant lymphoma, 1). All nodules were scored in accordance with the Liver Imaging Reporting and Data System (LI-RADS v2014), with or without consideration of ring-like enhancement in multiphasic HAP images as a major feature. In the multiphasic HAP group, 178 of 191 HCCs were scored as LR-3 to LR-5 (3 [1.69%], 85 [47.8%], and 90 [50.6%], respectively). Upon considering ring-like enhancement in multiphasic HAP images as a major feature, 5 more HCCs were scored as LR-5 (95 [53.4%]), which was a significantly more confident diagnosis than that with single HAP images (295 of 306 HCCs scored as LR-3 to LR-5: 13 [4.41%], 147 [49.8%], and 135 [45.8%], respectively; P = 0.0296). There was no significant difference in false-positive or false-negative diagnoses between the multiphasic and single HAP groups (P = 0.8400 and 0.1043, respectively). Multiphasic HAP imaging can improve the confidence of diagnosis of HCCs in gadoxetic acid-enhanced magnetic resonance imaging.

Gadoxetic acid-enhanced high temporal-resolution hepatic arterial-phase imaging with view-sharing technique: Impact on the LI-RADS category

PurposeTo evaluate the value of view-sharing multi-hepatic arterial-phase (mHAP) imaging for diagnosis of hypervascular hepatocellular carcinoma (HCC). Materials and methodsForty-seven consecutive patients with HCC underwent gadoxetic acid-enhanced magnetic resonance (MR) imaging before angiographic and lipiodol CT. Hepatic arterial-phase images were obtained at 5 consecutive phases with shared central k-space of 25%, followed by portal venous, late (2 and 3min), and hepatobiliary phase imaging. One-hundred-eight HCC nodules (size: 5–88mm, mean size: 18.2mm) confirmed on angiographic CT and lipiodol CT were evaluated for LI-RADS category and compared with single arterial-phase and mHAP findings regarding wash out, capsule, corona enhancement, and image quality. ResultsTwenty-four HCCs (22.2%) (size: 6–19mm, mean size: 12.3mm) were categorized as LR-3 based on the single arterial-phase. Capsule appearance (25.9%) and washout (57.4%) were most frequently observed in late phase (2min). Corona enhancement was observed in 73.1% of all HCCs on mHAP. For the 24 HCCs of LR-3, corona enhancement was observed in 75% on mHAP and contributed to upgrade category. No significant difference was found in the frequency of corona enhancement between mHAP and angiographic CT (P=0.11). Image quality was valued as good or excellent in all cases. ConclusionView-sharing mHAP was feasible without compromising image quality and contributed to the improvement in diagnostic confidence for hypervascular HCC in gadoxetic acid-enhance MR imaging.

TWIST-VIBE five-arterial-phase technology decreases transient severe motion after bolus injection of Gd-EOB-DTPA

To investigate whether time-resolved imaging with interleaved stochastic trajectories (TWIST)-volumetric interpolated breath-hold examination (VIBE) hepatic arterial phase imaging technique improves image quality in patients experiencing transient severe motion (TSM) during abdominal magnetic resonance imaging (MRI) with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA). This retrospective study compares TSM in MRI images from 28 patients with focal liver lesions imaged with gadopentetic acid (Gd-DTPA) and 28 patients with focal liver lesions imaged with Gd-EOB-DTPA. Images were taken during the precontrast phase, five hepatic arterial phases acquired with a single breath-hold, portal venous phase, and late dynamic phase. There was a significant difference in the mean motion scores for the arterial phase in Gd-EOB-DTPA cohort before, and after, enhancement (p<0.001); however, there was no significant difference in the Gd-DTPA cohort for the same (p<0.05). The mean motion scores in the five hepatic arterial phases in the Gd-EOB-DTPA cohort after enhancement were significantly higher than that in the Gd-DTPA cohort (p<0.001). TSM occurred significantly more frequently in the Gd-EOB-DTPA cohort (64.2%) than in the Gd-DTPA cohort (3.5%, p<0.001). The highest motion score in Gd-EOB-DTPA cohort occurred during the fourth arterial phase, which was significantly higher than the other four arterial phases after enhancement (p<0.001). Moderate and severe TSM (motion score ≥3) occurred mainly in the mid and mid-late arterial phase. All patients with arterial phase images affected by TSM (motion scores ≥3) had at least one arterial phase image with TSM score <3, which was of adequate image quality for diagnostic purposes. The TWIST-VIBE hepatic arterial phase imaging technique can be used to acquire arterial images at abdominal MRI with Gd-EOB-DTPA, and these images have adequate quality for diagnosis in patients who are affected by TSM.

The Short Breath-Hold Technique, Controlled Aliasing in Parallel Imaging Results in Higher Acceleration, Can Be the First Step to Overcoming a Degraded Hepatic Arterial Phase in Liver Magnetic Resonance Imaging: A Prospective Randomized Control Study.

The aim of this study was to assess whether a short breath-hold technique can improve hepatic arterial phase (HAP) image quality in gadoxetic acid-enhanced magnetic resonance (MR) imaging compared with a conventional long breath-hold technique. Institutional review board approval and patient consent were obtained for this prospective randomized control study. One hundred nineteen patients undergoing gadoxetic acid-enhanced MR imaging were randomly assigned to groups A or B. Group A patients underwent an 18-second long breath-hold MR technique (conventional VIBE [volumetric interpolated breath-hold examination] technique with GRAPPA [generalized autocalibrating partially parallel acquisition]), and group B patients underwent a 13-second short breath-hold MR technique (VIBE technique with CAIPIRINHA [controlled aliasing in parallel imaging results in higher acceleration]). Respiratory-related graphs of the precontrast and HAP were acquired. The breath-hold degree was graded based on the standard deviation (SD) value of respiratory waveforms. Gadoxetic acid-related dyspnea was defined as when the SD value of the HAP was 200 greater than that of the precontrast phase without degraded image quality in the portal and transitional phases (SD value of the HAP - SD value of the precontrast phase). The overall image quality and motion artifacts of the precontrast and HAP images were evaluated. The groups were compared using the Student t or Fisher exact test, as appropriate. The incidence of breath-holding difficulty (breath-hold grades 3 and 4) during the HAP was 43.6% (27/62) and 36.8% (21/57) for group A and B, respectively. The SD value during the precontrast phase and the SD value difference between the precontrast and HAP were both significantly higher in group A than in group B (P = 0.047 and P = 0.023, respectively). Gadoxetic acid-related dyspnea was seen in 19.4% (12/62) of group A and 7.0% (4/57) of group B. Group B showed better precontrast and HAP image quality than group A (P < 0.001). Degraded HAP (overall image quality ≥4) was observed in 9.7% (6/62) and 3.5% (2/57) of group A and B, respectively. The short breath-hold MR technique, CAIPIRINHA, showed better HAP image quality with less degraded HAP and a lower incidence of breath-hold difficulty and gadoxetic acid-related dyspnea than the conventional long breath-hold technique.

Adoption of Splenic Enhancement to Time and Trigger the Late Hepatic Arterial Phase During MDCT of the Liver: Proof of Concept and Clinical Feasibility.

The purpose of this study was to prospectively investigate the clinical feasibility of adopting splenic enhancement for timing and triggering the acquisition of late hepatic arterial phase images during multiphasic liver MDCT for assessment of hypervascular tumors. Forty-eight patients (33 men, 15 women; median age, 59 years; chronic liver disease, 23 patients; portal venous hypertension, 17 patients) with a total of 81 hypervascular liver tumors underwent liver MDCT by random assignment to one of two scanning protocols. Scanning delay for the late hepatic arterial phase was determined by assessment of time-to-peak splenic enhancement (splenic-triggering protocol) or aortic enhancement (aortic-triggering protocol). Acquisition timing, vascular attenuation, liver attenuation and homogeneity, signal-to-noise ratio, tumor-to-liver contrast, and tumor-to-liver contrast-to-noise ratio were compared. Two blinded independent observers used Likert scales to score timing adequacy (3-point scale), diagnostic confidence (5-point scale), and per lesion conspicuity (4-point scale) for hypervascular tumor detection. The splenic- and aortic-triggering protocols had significant differences in mean late hepatic arterial phase imaging timing (splenic, 36 ± 6 seconds; aortic, 32 ± 3 seconds; p = 0.010). Images obtained with the splenic-triggering protocol had significantly better observer-based judgment of adequacy (splenic, 2.04; aortic, 1.58; p = 0.002). Mean attenuation and signal-to-noise ratios from liver and portal vein were significantly higher with the splenic- than with the aortic-triggering protocol (p < 0.0001). The splenic-triggering protocol was associated with significant improvement in homogeneity of liver attenuation (p < 0.0001). Although the splenic-triggering protocol was associated with significantly higher lesion conspicuity than was the aortic-triggering protocol (p = 0.022), there was no significant difference in tumor detection rate. Our results provide a clinical foundation for and proof of principle that the adoption of splenic enhancement renders an optimal temporal window for late hepatic arterial phase imaging during MDCT of the liver for assessment of hypervascular tumors.

Bone Metastases of Hepatocellular Carcinoma: Appearance on MRI Using a Standard Abdominal Protocol.

The purpose of this study is to describe the MRI features of hepatocellular carcinoma (HCC) bone metastases. Thirty-three consecutive patients were included. Two radiologists performed qualitative and quantitative analysis. The coordinator searched for clinical and epidemiologic features related to patients and their primary liver tumors. Earlier MRI studies were also reviewed to determine whether bone metastases were already present and prospectively identified. Descriptive statistics and the Lin concordance correlation coefficient were used. Chronic hepatitis C virus infection was the most common cause of liver disease (20/32; 62.5%), and diffuse and multifocal HCC were the most frequent types of liver HCCs (28/33; 84.8%). Most lesions were located at the spine (109/155; 70.3%), with high signal intensity on fat-suppressed T1-weighted (54/62; 87.1%) and T2-weighted (53/62; 85.5%) images. Bone metastases were predominantly nodular (48/62; 77.4%), confined to the vertebral body (40/60; 66.7%), and best visualized at the arterial phase (40/62; 64.5%). The ring pattern of enhancement was present in 23 of 62 lesions, and the remaining lesions showed diffuse enhancement. Thirty-five of 62 (56.4%) bone metastases showed arterial peak of enhancement. In 13 of 33 (39.9%) patients, bone metastases were not prospectively reported. Most patients with bone metastases had chronic hepatitis C virus infection and diffuse or multifocal HCC. Metastases are most commonly appreciated as hypervascular focal moderately intensely enhancing nodular masses on the hepatic arterial dominant phase images, with concomitant moderately high signal intensity on fat-suppressed T1- and T2-weighted images.

Minimally Required Iodine Dose for the Detection of Hypervascular Hepatocellular Carcinoma on 80-kVp CT.

The objective of our study was to determine the iodine dose per unit of body weight (BW) or body surface area (BSA) that is minimally required to detect hypervascular hepatocellular carcinoma (HCC) on 80-kVp CT. One hundred eleven patients (78 men and 33 women; mean age, 68 years; age range, 43-85 years) with chronic hepatitis were randomized into three groups with different iodine loads (0.5, 0.4, and 0.3 g I/kg BW) and underwent contrast-enhanced CT at 80 kVp. Enhancement of the liver and of hypervascular HCCs was quantitatively and qualitatively assessed on hepatic arterial, portal venous, and equilibrium phase images and compared between the groups. Values for iodine dose per unit of BSA (g I/m(2)) were also computed and analyzed. No significant differences in the contrast-to-noise ratio (CNR) of hypervascular HCCs in any phase were found between the groups (p = 0.34-0.99). In the portal venous phase, the mean increase in hepatic contrast enhancement (ΔHU) of the 0.5 g I/kg group (80.3 HU) was higher than those of the 0.4 g I/kg (63.4 HU) and 0.3 g I/kg (53.3 HU) groups (p < 0.001). Linear correlation equations for the increase in hepatic contrast enhancement were as follows: ΔHU = 5.9 + 150.0 × IL(BW) (r = 0.69, p < 0.001), where IL(BW) is the iodine load per unit of BW (g I/kg), and ΔHU = 13.0 + 3.68 × IL(BSA) (r = 0.66, p < 0.001), where IL(BSA) is the iodine load pre unit of BSA (g I/m(2)). The minimal iodine dose required to achieve a tumor-to-liver CNR that is acceptable for the detection of hypervascular HCCs on 80-kVp CT was 0.3 g I/kg BW or 11.0 g I/m(2) BSA.

Hepatic Arterial Phase in Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging: Analysis of Respiratory Patterns and Their Effect on Image Quality.

The aims of this study were to objectively evaluate patient respiration and breathing change after contrast injection and to assess its potential impact on image quality for the hepatic arterial phase in gadoxetic acid-enhanced magnetic resonance imaging. This retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. One hundred fifty-four patients underwent gadoxetic acid-enhanced liver magnetic resonance imaging with a 13-second breath-hold hepatic arterial phase. During the acquisition of precontrast and hepatic arterial phases, the respiratory motion signal was acquired and graded on a 4-point scale based on the SD of the respiratory waveform, with the highest grade indicating the worst breath-hold. Breath-holding grades 3 and 4 for the hepatic arterial phases were considered as breath-holding difficulty during the hepatic arterial phase. Gadoxetic acid-related dyspnea was defined as when the SD value of respiratory waveform during the hepatic arterial phase was 200 greater than that of the precontrast image. Then, the precontrast and hepatic arterial phase images were evaluated with respect to overall image quality and motion artifact using a 5-point scale, with the highest score indicating the worst image quality. In the hepatic arterial phase, the correlation between breath-holding degree and image quality parameters was evaluated using Pearson correlation. The differences in mean image quality scores between patients with and without gadoxetic acid-related dyspnea were evaluated using Student t test. Based on the analysis of the respiratory waveforms, the incidence of breath-holding difficulty during the hepatic arterial phase was 23.4% (33/154), and the incidence of gadoxetic acid-related dyspnea was 6.5% (10/154). By image analysis, the incidence of a degraded hepatic arterial phase (overall image quality score ≥4) was 5.2% (8/154). During the hepatic arterial phase, the breath-holding degree correlated with overall image quality and motion artifacts (r = 0.564 and 0.578, respectively). Patients with gadoxetic acid-related dyspnea showed significantly worse image qualities of the hepatic arterial phase than patients without gadoxetic acid-related dyspnea (all, P < 0.001), although image qualities for the precontrast image were not statistically significant between the 2 groups (all, P > 0.05). The objective analysis of respiratory patterns during a breath-hold is feasible and useful for evaluating gadoxetic acid-related dyspnea and its effect on image quality analysis.

Can combining triple-arterial phase acquisition with fluoroscopic triggering provide both optimal early and late hepatic arterial phase images during gadoxetic acid-enhanced MRI?

To determine whether triple-arterial phase acquisition with fluoroscopic triggering can provide both well-timed early and late hepatic arterial phase (HAP) images more frequently than when using a fixed-time delay during gadoxetic acid-enhanced magnetic resonance imaging (MRI). Written informed consent was obtained for this Institutional Review Board (IRB)-approved prospective, Health Insurance Portability and Accountability Act (HIPAA)-compliant study. Ninety patients underwent gadoxetic acid-enhanced MRI at 3T with a single-breath-hold triple-arterial phase acquisition using either a fixed-time delay (n = 45) or fluoroscopic triggering injection protocol (n = 45). Three radiologists, blinded to method of timing and other data, independently determined whether well-timed early or late HAP were obtained for each arterial phase image set and assessed for transient severe motion (TSM). Rates of successful HAP acquisitions and of TSM were compared between the two protocols using χ(2) or Fisher's exact test. The rate of successful acquisition of late HAP images was similar in the two groups (93% [42/45] for fixed-time delay vs. 98% [44/45] for fluoroscopic triggering, P = 0.62). There was a trend toward higher rates of successful acquisition of both early and late HAP images in the fluoroscopic triggering group (69% [31/45] vs. 49% [22/45], P = 0.05). TSM occurred in five patients (6% [5/90]) and at similar frequencies in the two groups (2% [1/45] vs. 9% [4/45], P = 0.36). Triple-arterial phase acquisition with fluoroscopic triggering tended to provide both well-timed early and late HAP images more frequently than when using a fixed-time delay during gadoxetic acid-enhanced MRI.

Re-evaluation of detectability of liver metastases by contrast-enhanced CT: added value of hepatic arterial phase imaging.

We compared the detectability of liver metastases on 2- and 3-phase images using robust statistical methods. Nine radiologists evaluated unenhanced CT plus portal venous phase (2-phase) images and 2-phase plus hepatic arterial phase (HAP) (3-phase) images. Our study included 54 patients with primary malignant tumors who underwent 3-phase hepatic dynamic CT more than twice to screen for liver metastases; 24 had 1-6 liver metastases measuring 4-27 mm in diameter (median 13 mm). The other 30 had no metastases. Nine board-certified radiologists participated in our observer performance study. They specified the location of the metastatic lesions and rated the probability of metastatic nodules on 2-phase images acquired with and without HAP imaging. We used jackknife alternative free-response receiver operating characteristic (JAFROC) analysis to compare their performances. For all radiologists the area under the curve without and with HAP imaging was 0.86 and 0.88, respectively; the difference was significant (p = 0.04). For metastases smaller than 10 mm the averaged lesion localization fraction without and with HAP imaging was 0.17 and 0.26 (p < 0.01). Adding HAP to 2-phase imaging improved the detectability of liver metastases, especially of lesions smaller than 10 mm.

Usefulness of Controlled Aliasing in Parallel Imaging Results in Higher Acceleration in Gadoxetic Acid–Enhanced Liver Magnetic Resonance Imaging to Clarify the Hepatic Arterial Phase

We aimed to determine whether the controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) technique could improve the image quality of the hepatic arterial phase of gadoxetic acid-enhanced liver magnetic resonance (MR) imaging. A total of 320 patients underwent gadoxetic acid-enhanced liver MR imaging: a conventional protocol (a fixed scan delay and 2-mL/s injection) using a standard 3-T MR system (Trio-Tim; Siemens, commercialized since 2005) (group A), an optimized protocol (bolus tracking and 1-mL/s injection) using a standard 3-T MR (group B), an optimized protocol using a new 3-T MR (Skyra; Siemens, commercialized since 2012) (group C), and an optimized protocol with CAIPIRINHA using a new 3-T MR (group D). The image quality of the hepatic arterial phase was graded using a 4-point rating scale from 1 (no artifacts) to 4 points (non-diagnostic images with severe artifacts). The differences in image quality scores among the 4 groups were evaluated. In addition, the detection rates of hypervascular hepatocellular carcinomas among the 4 groups were evaluated. Scores of 4 points were observed in groups A (n = 7), B (n = 5), and C (n = 3) but not in group D. The median image quality score was 2 in groups A and B and 1 in groups C and D. From group A to group D, the median image quality score decreased significantly (P = 0.0001). The median image quality score was significantly lower in group D than in groups A and B (P = 0.0001 and 0.001, respectively), whereas there was no significant difference observed between groups C and D (P = 0.656). The detection rates of hypervascular hepatocellular carcinomas on the hepatic arterial phase were not significantly different among the groups (all P > 0.03), except between groups A and D (P = 0.007). The CAIPIRINHA technique improved the image quality of hepatic arterial phase imaging with gadoxetic acid, reducing the number of non-diagnostic arterial phase studies.